Suppr超能文献

Index60 可识别出 2 小时血糖水平正常的自身抗体阳性人群中处于 3 期风险的个体:对当前 1 型糖尿病分期标准的影响。

Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes.

机构信息

University of Minnesota, Minneapolis, MN.

Baylor College of Medicine, Texas Children's Hospital, Houston, TX.

出版信息

Diabetes Care. 2022 Feb 1;45(2):311-318. doi: 10.2337/dc21-0944.

Abstract

OBJECTIVE

We assessed whether Index60, a composite measure of fasting C-peptide, 60-min C-peptide, and 60-min glucose, could improve the metabolic staging of type 1 diabetes for progression to clinical disease (stage 3) among autoantibody-positive (Ab+) individuals with normal 2-h glucose values (<140 mg/dL).

RESEARCH DESIGN AND METHODS

We analyzed 3,058 Type 1 Diabetes TrialNet Pathway to Prevention participants with 2-h glucose <140 mg/dL and Index60 <1.00 values from baseline oral glucose tolerance tests. Characteristics associated with type 1 diabetes (younger age, greater Ab+, higher HLA DR3-DQ2/DR4-DQ8 prevalence, and lower C-peptide) were compared among four mutually exclusive groups: top 2-h glucose quartile only (HI-2HGLU), top Index60 quartile only (HI-IND60), both top quartiles (HI-BOTH), and neither top quartile (LO-BOTH). Additionally, within the 2-h glucose distribution of <140 mg/dL and separately within the Index60 <1.00 distribution, comparisons were made between those above or below the medians.

RESULTS

HI-IND60 and HI-BOTH were younger, with greater frequency of more than two Ab+, and lower C-peptide levels, than either HI-2HGLU or LO-BOTH (all P < 0.001). The cumulative incidence for stage 3 was greater for HI-IND60 and HI-BOTH than for either HI-2HGLU or LO-BOTH (all P < 0.001). Those with Index60 values above the median were younger and had higher frequency of two or more Ab+ (P < 0.001) and DR3-DQ2/DR4-DQ8 prevalence (P < 0.001) and lower area under the curve (AUC) C-peptide levels (P < 0.001) than those below. Those above the 2-h glucose median had higher AUC C-peptide levels (P < 0.001), but otherwise did not differ from those below.

CONCLUSIONS

Index60 identifies individuals with characteristics of type 1 diabetes at appreciable risk for progression who would otherwise be missed by 2-h glucose staging criteria.

摘要

目的

我们评估 Index60(空腹 C 肽、60 分钟 C 肽和 60 分钟血糖的综合指标)是否可以改善 1 型糖尿病的代谢分期,以预测自身抗体阳性(Ab+)且 2 小时血糖值正常(<140mg/dL)的个体向临床疾病(第 3 期)的进展。

研究设计和方法

我们分析了来自 1 型糖尿病试验网预防途径的 3058 名参与者,他们在基线口服葡萄糖耐量试验中有 2 小时血糖值<140mg/dL 和 Index60 值<1.00。在四个相互排斥的组中比较了与 1 型糖尿病相关的特征(年龄较小、Ab+更多、HLA DR3-DQ2/DR4-DQ8 患病率更高、C 肽水平更低):仅 2 小时血糖最高四分位数(HI-2HGLU)、仅 Index60 最高四分位数(HI-IND60)、两者均为最高四分位数(HI-BOTH)和两者均不在最高四分位数(LO-BOTH)。此外,在<140mg/dL 的 2 小时血糖分布内,并分别在 Index60<1.00 的分布内,比较了高于或低于中位数的个体。

结果

HI-IND60 和 HI-BOTH 比 HI-2HGLU 或 LO-BOTH 更年轻,Ab+的频率更高,且 C 肽水平更低(均 P<0.001)。HI-IND60 和 HI-BOTH 的第 3 期累积发生率大于 HI-2HGLU 或 LO-BOTH(均 P<0.001)。Index60 值高于中位数的个体更年轻,Ab+的频率更高(P<0.001),且 DR3-DQ2/DR4-DQ8 患病率(P<0.001)和 AUC C 肽水平(P<0.001)更低。那些 2 小时血糖值高于中位数的个体的 AUC C 肽水平更高(P<0.001),但其他方面与低于中位数的个体没有差异。

结论

Index60 可识别出具有 1 型糖尿病特征的个体,他们处于明显的进展风险中,否则将被 2 小时血糖分期标准所遗漏。

相似文献

3
Index60 as an additional diagnostic criterion for type 1 diabetes.
Diabetologia. 2021 Apr;64(4):836-844. doi: 10.1007/s00125-020-05365-4. Epub 2021 Jan 26.
4
Index60 Is Superior to HbA1c for Identifying Individuals at High Risk for Type 1 Diabetes.
J Clin Endocrinol Metab. 2022 Sep 28;107(10):2784-2792. doi: 10.1210/clinem/dgac440.
5
Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.
Diabetes Care. 2017 Nov;40(11):1494-1499. doi: 10.2337/dc17-0916. Epub 2017 Aug 31.
6
8
The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening.
Diabetologia. 2020 Mar;63(3):588-596. doi: 10.1007/s00125-019-05047-w. Epub 2019 Nov 25.

引用本文的文献

2
IA-2A positivity increases risk of progression within and across established stages of type 1 diabetes.
Diabetologia. 2025 May;68(5):993-1004. doi: 10.1007/s00125-025-06382-x. Epub 2025 Feb 28.
3
A Glucose Fraction Independent of Insulin Secretion: Implications for Type 1 Diabetes Progression in Autoantibody-Positive Cohorts.
Diabetes Technol Ther. 2025 Mar;27(3):179-186. doi: 10.1089/dia.2024.0422. Epub 2025 Jan 6.
4
Leveraging artificial intelligence and machine learning to accelerate discovery of disease-modifying therapies in type 1 diabetes.
Diabetologia. 2025 Mar;68(3):477-494. doi: 10.1007/s00125-024-06339-6. Epub 2024 Dec 19.
5
Time to reframe the disease staging system for type 1 diabetes.
Lancet Diabetes Endocrinol. 2024 Dec;12(12):924-933. doi: 10.1016/S2213-8587(24)00239-0.
6
Trajectory of beta cell function and insulin clearance in stage 2 type 1 diabetes: natural history and response to teplizumab.
Diabetologia. 2025 Mar;68(3):646-661. doi: 10.1007/s00125-024-06323-0. Epub 2024 Nov 19.
8
Identification of type 1 diabetes risk phenotypes using an outcome-guided clustering analysis.
Diabetologia. 2024 Nov;67(11):2507-2517. doi: 10.1007/s00125-024-06246-w. Epub 2024 Aug 6.
9
Beyond Stages: Predicting Individual Time Dependent Risk for Type 1 Diabetes.
J Clin Endocrinol Metab. 2024 Nov 18;109(12):3211-3219. doi: 10.1210/clinem/dgae292.
10
Endpoints for clinical trials in type 1 diabetes drug development.
Lancet Diabetes Endocrinol. 2024 May;12(5):297-299. doi: 10.1016/S2213-8587(24)00097-4.

本文引用的文献

1
Index60 as an additional diagnostic criterion for type 1 diabetes.
Diabetologia. 2021 Apr;64(4):836-844. doi: 10.1007/s00125-020-05365-4. Epub 2021 Jan 26.
2
The clinical consequences of heterogeneity within and between different diabetes types.
Diabetologia. 2020 Oct;63(10):2040-2048. doi: 10.1007/s00125-020-05211-7. Epub 2020 Sep 7.
3
One-Hour Oral Glucose Tolerance Tests for the Prediction and Diagnostic Surveillance of Type 1 Diabetes.
J Clin Endocrinol Metab. 2020 Nov 1;105(11):e4094-101. doi: 10.1210/clinem/dgaa592.
4
2. Classification and Diagnosis of Diabetes: .
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31. doi: 10.2337/dc20-S002.
5
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.
Diabetes Care. 2020 Jan;43(1):5-12. doi: 10.2337/dc19-0880. Epub 2019 Nov 21.
6
1-Hour Post-OGTT Glucose Improves the Early Prediction of Type 2 Diabetes by Clinical and Metabolic Markers.
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1131-1140. doi: 10.1210/jc.2018-01828.
7
β Cell dysfunction exists more than 5 years before type 1 diabetes diagnosis.
JCI Insight. 2018 Aug 9;3(15). doi: 10.1172/jci.insight.120877.
8
Adult-onset autoimmune diabetes: current knowledge and implications for management.
Nat Rev Endocrinol. 2017 Nov;13(11):674-686. doi: 10.1038/nrendo.2017.99. Epub 2017 Sep 8.
9
Dysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials.
Diabetes Care. 2017 Nov;40(11):1494-1499. doi: 10.2337/dc17-0916. Epub 2017 Aug 31.
10
Early prediction of autoimmune (type 1) diabetes.
Diabetologia. 2017 Aug;60(8):1370-1381. doi: 10.1007/s00125-017-4308-1. Epub 2017 May 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验